Home
/ Amarin
/ Competitors

Amarin Competitors and Similar CompaniesClear all

Amarin's competitors and similar companies include Horizon Therapeutics, Afimmune, Matinas BioPharma, Micelle BioPharma and Acasti Pharma.

	Amarin Amarin Corporation is a pharmaceutical company that engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases.	Horizon Therapeutics Horizon Therapeutics is a biopharmaceutical company focused on researching, developing, and commercializing medicines.	Afimmune Afimmune is a drug discovery and development company focusing on fibrotic conditions.	Matinas BioPharma Matinas BioPharma is a biopharmaceutical company developing a drug candidate for the treatment of cardiovascular and metabolic conditions.	Micelle BioPharma Micelle BioPharma is an integrated pharmaceutical company.	Acasti Pharma Acasti is a biopharmaceutical company focused on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil.
Founding Date	Founding Date 1991	Founding Date 2008	Founding Date N/A	Founding Date 2011	Founding Date 2018	Founding Date 2002
Type	Type Public	Type Subsidiary	Type Private	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech contractor drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Dublin, IE HQ Zug, CH Bridgewater Township, US	Locations Dublin, IE HQ	Locations Dublin, IE HQ	Locations Bedminster, US HQ Raritan, US	Locations West Palm Beach, US HQ Riviera Beach, US	Locations Laval, CA HQ Laval, CA New York, US
Employees	Employees 275	Employees 2,649	Employees 13	Employees 2140% increase	Employees 3	Employees 32
Valuation ($)	Valuation ($) 257.6 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 14 m	Valuation ($) N/A	Valuation ($) 34.2 m
Financial
Revenue (est.)	Revenue (est.) $228.6m (FY, 2024)	Revenue (est.) $3.6b (FY, 2022)	Revenue (est.) N/A	Revenue (est.) $1.1m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $920.2m (FY, 2022)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit $81.4m (FY, 2024)	Gross profit $2.7b (FY, 2022)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit N/A
Net income	Net income ($82.2m) (FY, 2024)	Net income $521.5m (FY, 2022)	Net income N/A	Net income ($22.9m) (FY, 2023)	Net income N/A	Net income ($12.9m) (FY, 2024)
Funding
Total funding raised	Total funding raised $ 122.8m	Total funding raised $ 63m	Total funding raised N/A	Total funding raised $ 55m	Total funding raised N/A	Total funding raised N/A